ScreenPoint Insights

Your home for information and innovation in mammography and Breast AI.

Podcast: ScreenPoint Co-Founder Talks Future of Breast Cancer Screening

Podcast: ScreenPoint Co-Founder Talks Future of Breast Cancer Screening

Nico Karssemeijer, Chief Science Officer and Co-Founder of ScreenPoint Medical, joins Impact AI podcast to discuss how his team is revolutionizing breast cancer screening through cutting-edge AI.

June 10, 2025
Study from UCLA shows Transpara could help identify hidden breast cancer

Study from UCLA shows Transpara could help identify hidden breast cancer

New research suggests Transpara Detection can be used to spot cancers radiologist may miss

April 30, 2025
ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload

ScreenPoint Medical: AI-Enhanced Mammography Screening Significantly Improves Breast Cancer Detection and Reduces Radiologist Workload

Only randomized controlled trial of its kind highlights impact of Transpara Breast AI

February 10, 2025
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities

ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities

Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.

January 08, 2025
Transpara Announces New FDA Clearance at RSNA 2024

Transpara Announces New FDA Clearance at RSNA 2024

SPM Showcases Innovative FDA Cleared Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance

December 02, 2024
Transpara Improves Cancer Detection by Decreasing False Negative Cancers

Transpara Improves Cancer Detection by Decreasing False Negative Cancers

Transpara Accurately Identified Half of False Negative Cancers – all Invasive, and Often in Dense Breasts – in a Large Retrospective Study

November 19, 2024

Looking for more? Visit our Evidence page for the latest groundbreaking research in Breast AI. Visit page →